Abbott clinical biochemical direct bilirubin test group - Taiwan Registration 1120768ac114e4c319c5b63c9de22bd6
Access comprehensive regulatory information for Abbott clinical biochemical direct bilirubin test group in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 1120768ac114e4c319c5b63c9de22bd6 and manufactured by ABBOTT GMBH;; SEKISUI DIAGNOSTICS P.E.I. INC.. The authorized representative in Taiwan is ABBOTT LABORATORIES SERVICES LLC TAIWAN BRANCH (U.S.A.).
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Device Details
Registration Details
1120768ac114e4c319c5b63c9de22bd6
DHA00602335906
Product Details
The quantitative measurement of direct bilirubin concentration in human serum or plasma should be used with the ARCHITECT c system (c 4000, c 8000, c16000) and the AEROSET system.
A Clinical chemistry and clinical toxicology
A.1110 Bilirubin (total or direct) test system
Input;; Contract manufacturing
Dates and Status
Mar 19, 2012
Mar 19, 2027